Purpose Apolipoprotein D (ApoD) is a lipocalin participating in lipid transport. It binds to a variety of ligands, with a higher affinity for arachidonic acid, and is thought to have a diverse array of functions. We investigated a potential role for ApoD in insulin sensitivity, inflammation, and thrombosis-processes related to lipid metabolism-in severely obese women. Methods We measured ApoD expression in a cohort of 44 severely obese women including dysmetabolic and nondysmetabolic patients. Physical and metabolic characteristics of these women were determined from anthropometric measurements and blood samples. ApoD was quantified at the mRNA and protein levels in samples from three intra-abdominal adipose tissues (AT): omental, mesenteric and round ligament (RL). Results ApoD protein levels were highly variable between AT of the same individual. High ApoD protein levels, particularly in the RL depot, were linked to lower plasma insulin levels (−40%, p = 0.015) and insulin resistance (−47%, p = 0.022), and increased insulin sensitivity (+10%, p = 0.008). Lower circulating pro-inflammatory PAI-1 (−39%, p = 0.001), and TNF-α (−19%, p = 0.030) levels were also correlated to high ApoD protein in the RL AT. Conclusions ApoD variability between AT was consistent with different accumulation efficiencies and/or metabolic functions according to the anatomic location of fat depots. Most statistically significant correlations implicated ApoD protein levels, in agreement with protein accumulation in target tissues. These correlations associated higher ApoD levels in fat depots with improved metabolic health in severely obese women.
Introduction
Obesity, defined as an excessive accumulation of body fat, is a condition steadily increasing in prevalence in developed and developing countries. There are now approximately 2.1 billion people that are overweight or obese worldwide [1] . In western countries, a common clinical definition of obesity is a body mass index (BMI) above 30 kg/m 2 . Obesity is further separated in three classes: class I with a BMI ≥ 30.0 kg/m 2 , class II with a BMI ≥ 35.0 kg/m 2 and class III with a BMI ≥ 40.0 kg/m 2 [2] . The global obesity crisis is of importance as obesity is a major risk factor for health complications including cardiovascular disease, metabolic syndrome, type 2 diabetes, and chronic inflammation [2] .
Inflammation has been found to be both a consequence of and a contributing factor to fat accumulation [3, 4] . The expansion of adipose tissues (ATs) results in their invasion by polarized M1 macrophages, which secrete pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) [5] . Adipocytes also contribute to IL-6 secretion [6] . Fat accumulation and proinflammatory cytokine secretion increase together during the development of obesity, resulting in particularly highplasma cytokine levels in class III obese individuals [7] . Chronic inflammation, in turn, impairs insulin signaling, and sensitivity [3, 4] and promotes AT expansion [8] . However, some obese individuals maintain almost normal insulinemia and insulin sensitivity. These patients-often referred to as non-dysmetabolic-tend to show lower levels of circulating cytokines compared to their dysmetabolic counterparts [7] . While AT expansion is strongly correlated with an aggravation of the metabolic profile, some fat depots are less deleterious than others [9] . Some AT, like the brown fat, are even considered beneficial [10] . The presence of round ligament (RL) fat in obese individuals has been considered relatively protective as it produces less pro-inflammatory factors than mesenteric (ME) and omental (OM) fat depots [11] .
Apolipoproteins are a class of proteins that bind and transport lipids through the circulatory and lymphatic systems. ApoD is a glycosylated 19-to-32 kDa protein member of the lipocalin superfamily that possesses a pocket able to bind to a large array of small hydrophobic ligands. Among these ligands are arachidonic acid (ARA), bilirubin, and a large number of steroids [12] . While ApoD is mostly expressed in the nervous system, reproductive glands, adrenal glands, kidney, lung, spleen, pancreas, and placenta [12] , it is also expressed in AT [12, 13] . Most of the research on ApoD has focused on its neuroprotective and anti-inflammatory functions in neurodegenerative diseases [14] [15] [16] [17] [18] [19] [20] [21] . However, considering its high-plasma level (about 12 mg/100 mL) [22] , ApoD is expected to play some functions related to lipid metabolism outside of the nervous system. In fact, there is a direct link between ApoD deficiency and insulin resistance (IR) in mice. ApoD knockout mice show higher plasma insulin and triacylglycerol (TAG) levels, and lower epididymal lipoprotein lipase (LPL) levels [23] , while transient hepatic ApoD overexpression increases serum LPL activity and reduces circulating TAG [24] . Moreover, long-term neuronal overexpression of ApoD induces non-inflammatory hepatic steatosis and IR in 1-year-old transgenic mice [25, 26] . Links between ApoD and insulin signaling/lipid metabolism can also be found in humans: a significant association exists between ApoD polymorphism and diabetes, obesity as well as hyperinsulinemia [27, 28] . ApoD adrenal gland expression is strongly downregulated in Cushing syndrome due to macronodular adrenal hyperplasia [29] . To date there have been no reports of humans with a complete deficiency in plasma ApoD.
In light of these facts, we postulated that ApoD plays a role in AT metabolism and control of inflammation. As such, we searched for a potential link between the metabolic profile of severely obese individuals and ApoD expression in different intra-abdominal fat depots obtained during bariatric surgery.
Materials and methods

Patient selection
This study included 44 Caucasian premenopausal severely obese women with a mean BMI of 53.6 kg/m 2 , who were candidates for biliopancreatic diversion with duodenal switch surgery at the Quebec Heart and Lung University Institute Hospital [30] . Subjects with hepatotoxic medication, history of hepatitis, prior weight-loss surgery, smoking and/or consuming more than 100 g of alcohol per week were excluded. Thirteen women were diabetic according to the Diagnosis and Classification of Diabetes Mellitus WHO guidelines. Although diabetic subjects were treated pharmacologically for their condition, none were treated with glitazones. The appropriate ethics committee approved the experimental design (Laval University Ethics Committee approval CERUL # 2004-108), and all participants provided their written informed consent.
Anthropometric measurements and blood sampling
Patients were weighed in a light gown on an electronic Toledo scale adapted for body weight greater than 136 kg, and BMI was calculated as the ratio of weight (kg) to height squared (m 2 ). Body fat distribution was assessed using waist circumference measured in a standard position at the widest circumference of the umbilical level. Blood sampling was performed in the morning after an overnight fast (12 h minimum). Plasma cholesterol, HDL-cholesterol, lowdensity lipoprotein-cholesterol, TAG, and fasting glucose concentrations were evaluated by routine methods in the clinical laboratories of the Heart and Lung University Institute Hospital in Quebec City. Plasma insulin concentrations were determined with a high-sensitivity ELISA (Millipore, EZHI-14K). IR based on the "Homeostasis Model Assessment" (HOMA) index was evaluated according to the following equation: insulin (µUI/mL) x glucose (mmol/L)/22.5 [31] , whereas the "Quantitative Insulin Check Index" (QUICKI), which reflects insulin sensitivity was calculated as follows: 1/log [(fasting insulin) (μUI/mL) × (fasting glucose) (mg/dL)] [32] . Plasma TNF-α and IL-6 concentrations were measured with a highsensitivity ELISA (R&D Systems, DTA00C, and D6050). The run-to-run coefficients of variation were less than 10% for IL-6 and TNF-α [33] . Finally, another blood sample was collected in plastic tubes containing trisodium citrate anticoagulant with great care in order to minimize platelet activation. Plasma plasminogen activator inhibitor-1 (PAI-1) antigen levels were measured with the Asserachrom PAI-1 ELISA kit (DiagnosticaStago, 00949US), and both intraand inter-assay coefficients of variation were <5% [34] .
Adipose tissue removal
AT samples were recovered during gastric bypass surgery following an overnight fast (at least 12 h). General anesthesia was induced by a short-acting barbiturate and maintained by fentanyl and a mixture of oxygen and nitrous oxide. Patients did not receive drugs acting on the autonomic nervous system or modifying catecholamine levels [33] . All fat depots under consideration are drained by the portal vein or its collaterals, and classified as intraabdominal [35] , and more particularly as intraperitoneal fat [36] . After surgical excision, AT samples of approximately 200 mg were obtained from the OM and ME depots [37, 38] , as well as from the RL fat surrounding the liver. From these samples, 100 mg were used for quantification of the ApoD mRNA levels in AT.
Immunoblotting
To prepare total protein extracts, 100 mg of AT samples were homogenized in lysis buffer (50 mM Tris-HCl pH 7.4, 250 mM sucrose, 1% v/v Triton X-10, 100 mM NaF, 10 mM Na-pyrophosphate, 1 mM EDTA, 1 M DTT, 1 mM Na-vanadate, 1 mM PMSF). Samples were centrifuged at 23,000 × g for 20 min at 4 o C and the lipid layer and cell debris were discarded. Total protein concentration was measured using the Bradford Assay (Sigma Aldrich) [39] . For each sample, 10 µg total proteins were loaded and separated on a 10% SDS-polyacrylamide gel. The proteins were then transferred to PVDF membranes, blocked with 10% w/v skim milk (powder) in Tris-buffered saline (pH 7.4) supplemented with 0.1% v/v Tween and incubated with anti-human-ApoD mouse monoclonal antibody (clone 2B9; 1:1000) [40] . The primary antibody was then detected using anti mouse IgG conjugated to horseradish peroxidase (Cell Signaling, 7076 S; 1:1000) and visualized by chemiluminescence (Chemiluminescent HRP Substrate; Millipore). Amido Black staining was used as loading control [41] . Bands were quantified by densitometry using the Gel Analyzer function of Image J software.
Statistical analyses
Raw values for all measurements are included as supplementary material (Table S1 ). For cohort division according to ApoD protein levels, the median value was used as the cutoff point between low and high groups for each fat 
Results
ApoD expression levels correlate with improved metabolic markers in severely obese women Physical and metabolic characteristics of 44 severely obese women (classes II and III) were determined from body measurements and blood samples (Table 1 ). Although the "classical" dysmetabolic profile associated with obesity (i.e., hyperlipidemia and hyperglycemia) was observed, half of the women presented at least some metabolically healthy values such as high HDL-cholesterol, low circulating TAG and/or low insulin levels [42] . Samples from OM, ME, and RL AT were collected from these women during intraabdominal surgery [11] and the levels of ApoD mRNA and protein expression were measured. Mean ApoD protein levels were similar in all AT sampled (Fig. 1a) . However, we observed notable regional variations in ApoD Interleukin-6 (pg/mL) 4.6 ± 2.2 1.3-9.9
LDL low-density lipoprotein, HDL high-density lipoprotein, HOMA homeostasis model assessment, IR insulin resistance, QUICKI quantitative insulin sensitivity check index, PAI-1 plasminogen activator inhibitor-1, TNF-α tumor necrosis factor-α, SD standard deviation expression levels within the same individual. ApoD levels in any one AT did not correlate with ApoD levels in other fat depots (Fig. 1b) . Because different AT are thought to have various effects on metabolism [9, 10] , we examined potential associations between ApoD levels and the various biomarkers that were evaluated in these women. ApoD mRNA and protein levels correlated significantly with several biomarkers (Table 2) . More correlations were observed with ApoD protein levels than with mRNA levels, probably because ApoD is a circulating protein that can accumulate in target tissues [12] . Interestingly, the QUICKI insulin sensitivity index was positively associated with ApoD protein levels in all fat depots examined. In the ME fat, ApoD mRNA levels correlated negatively with circulating IL-6 while ApoD protein levels correlated negatively with circulating proinflammatory TNF-α. In the RL AT, ApoD protein levels were negatively associated with patient age and circulating pro-thrombotic PAI-1. Although not statistically significant, there was a trend towards a negative association between ApoD protein and fasting insulin levels in the RL fat depot. Altogether, these observations suggest a possible beneficial role for ApoD insulin signaling and inflammation.
ApoD protein levels in the round ligament fat are associated with improved insulin sensitivity and inflammation
We further explored the potential link between ApoD protein level assessed at the AT level and metabolic health by dividing the samples from severely obese women in two subgroups based on the ApoD protein level for each fat depot (around the median value; Supplementary Fig. S1 ). Since ApoD protein levels vary considerably between AT of the same individual, this division process resulted in different women being (sub)grouped together when different AT are considered.
In the RL AT, higher levels of ApoD protein were associated with lower BMI and waist circumference (Fig.  2a) as well as improved insulin metabolism: lower fasting insulin levels and HOMA-IR index, and higher QUICKI (Fig. 2b) . Interestingly, the QUICKI index was positively associated with ApoD levels in the OM fat and, while not statistically significant, an analogous trend was observed in the ME depot (p = 0.0591). Circulating PAI-1 and TNF-α were negatively associated with ApoD protein levels in the RL AT (Fig. 2c) . A trend toward low TNF-α was also associated with high ApoD levels in the ME fat (p = 0.0605). Plasma IL-6 levels were not linked to ApoD protein levels, irrespective of the AT examined.
In an effort to test the specificity and robustness of the links we uncovered between AT ApoD protein levels and metabolic markers, the samples from severely obese women were differently divided, this time according to BMI (BMI ≥ 50 kg/m 2 and 50 > BMI ≥ 40 kg/m 2 ; Fig. 3 ). As expected, this procedure resulted in two groups showing a significant difference in BMI and waist circumference (Fig.  3a) . No differences in ApoD protein levels were found between these groups, irrespective of the AT considered. Division of the cohort according to BMI showed better insulin metabolism in less obese women: lower fasting insulin levels and HOMA-IR index, and higher QUICKI (Fig. 3b) . While it was not associated with circulating PAI-1 or TNF-α levels, lower BMI was also linked to decreased IL-6 levels (Fig. 3c) . Similar results were obtained with a cohort division based on waist circumference (data not shown). Taken together, our observations suggest that the link between high ApoD levels and lower inflammatory markers (PAI-1 and TNF-α circulating levels) in severely obese women is specific to the accumulation of ApoD protein in particular AT depots such as the RL fat, and not merely a consequence of lower BMI. 
Conclusion
In this study, we demonstrated that the ApoD level in specific fat depots is associated with several metabolic factors. As ApoD is a circulating protein that can accumulate in specific tissues including liver and AT [12] , correlations with ApoD protein levels are probably more relevant to the patient's metabolic profile than ApoD mRNA levels. The source of human tissue (gastric bypass surgery patients) limited our study to mesenteric, omental and round ligament fat depots from severely obese women. AT samples collected for this study were heterogeneous, containing adipocytes but also stromal cells, including pre-adipocytes, macrophages, and lymphocytes. This heterogeneity may influence gene expression and protein level measurement (including ApoD and other relevant markers), depending on the proportion of each cell type, and should be kept in mind during interpretation of our results. Despite this caveat, interesting relationships were found in our analyses associating higher ApoD levels with improved metabolic health as inferred from lower levels of harmful biomarkers. Insulin sensitivity (as measured by QUICKI) was particularly correlated with ApoD protein levels in all fat depots examined. While thrombosis and inflammation markers correlated for the most part with ApoD protein levels in the RL fat.
ApoD protein levels were highly variable between AT of the same individual, suggesting different accumulation efficiencies and/or metabolic functions according to the anatomic location of fat depots. The mechanism of ApoD protein internalization by adipocytes could be critical in understanding this variability. The intriguing link we uncovered between ApoD protein level and age, suggesting that younger severely obese women may have more ApoD in their RL fat, could be explained by differences in ApoD internalization. The ApoD receptor Basigin (CD147) was recently identified in neurons [43] . This receptor is expressed in most if not all tissues, including AT [44] , and may, therefore, play a major role in ApoD internalization by fat. As such, the variability of ApoD accumulation in one AT compared to another might be due to its own Basigin levels. This, however, remains to be validated. On the other hand, the single correlation observed between ApoD mRNA level and IL-6 in the ME fat deposit ( Table 2) is indicative of a regulation mechanism at the transcriptional level. In fact, IL-6 has been shown to reduce the expression of ApoD in 293T cells [45] . However, it is not clear why evidence of this potential transcriptional regulation was only found in ME fat. This might constitute further evidence of functional differences between AT [46] [47] [48] .
A better resolution of ApoD's link with key metabolic health factors was observed after we divided the cohort into LDL-C, low-density lipoprotein-cholesterol; Insulin, fasting plasma insulin; QUICKI, quantitative insulin sensitivity check index; PAI-1, plasminogen activator inhibitor-1; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6.
high vs. low ApoD protein levels. This division revealed that higher levels of protein ApoD in the RL fat were linked to lower BMI and waist circumference, to improved insulin metabolism (as measured by three criteria: fasting insulin, HOMA-IR, and QUICKI) and to reduced systemic inflammation. Since a reduction of adiposity and abdominal fat accumulation (i.e., reduced BMI) has an impact on insulin sensitivity and chronic inflammation [2] , we examined the impact of BMI and waist circumference on those metabolic parameters in our cohort. Interestingly, when the cohort was divided according to BMI, the association with inflammation markers PAI-1 and TNF-α was lost. This argues for a critical link between ApoD protein levels and inflammation profile, specifically in the RL fat. Of note, IL-6 secretion was significantly different between BMI subgroups, a biomarker that was not linked to ApoD levels in our previous division. This would suggest that the links we observe between ApoD protein and inflammation are independent of BMI in severely obese women. Pioneering work on the physiological role of the RL AT has shown that it possesses distinct metabolic properties [49, 50] . Our analysis suggests a specific role for ApoD in the RL fat that appears different than for the other AT examined. In agreement, previous studies have shown different physiological roles for different AT depots [46] [47] [48] . However, it is unlikely that the RL AT on its own can significantly impact whole-body state/function given its surmised small size. Its mass has never been clearly determined in either normal or obese individuals but, because of its anatomical location between the falciform and the round Fig. 2 Metabolic profiles according to ApoD protein level of each fat depot. The cohort of severely obese women was divided into two groups, corresponding to high vs. low ApoD protein levels, around the median value in each AT: omental (OM, n = 44), mesenteric (ME, n = 36), and round ligament (RL, n = 43). We considered a anthropometric characteristics: body mass index (BMI) and waist circumference (WC); b insulin-related factors: fasting insulin level, homeostasis model assessmentinsulin resistance index (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI); as well as c inflammatory markers: plasminogen activator inhibitor-1 (PAI-1), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6). Histograms show mean value ± SEM. A Student's t-test was used to show statistically significant difference; * p < 0.05, ** p < 0.01 ligaments, its size is assumed to be restricted. Nonetheless, the RL AT could serve as an indicator that similar changes are occurring to other adipose depots or other tissue types throughout the body, and together they could have a significant physiological impact.
One possible mechanism of action for ApoD in fat depots is through its well-known role in the modulation of inflammation. Indeed, ApoD possesses inflammation repression functions [51, 52] ; it is, therefore, possible that ApoD can contribute to the reduction of TNF-α secretion observed in the high RL AT ApoD group. One mechanism for this ApoD property could be through ARA transport. ARA is the source of all eicosanoid production and an increase in the ARA supplied to AT's leukocytes is likely to increase eicosanoid production, of which prostaglandin E2 (PGE2) is a prime example. While low doses of PGE2 have a pro-inflammatory effect on leukocytes, higher doses of PGE2 actually inhibits leukocyte TNF-α secretion by increasing intracellular cAMP levels [53, 54] . This hypothesis has strong implications for insulin sensitivity, as TNF-α has been shown to inhibit insulin signaling and expression through c-Jun N-terminal kinase activation, which results in inhibition of insulin receptor substrate-1, Akt/protein kinase B, and insulin gene transcription [4] . Therefore, ApoD may indirectly promote insulin sensitivity through a reduction of TNF-α secretion. Also, the correlation we observed between ApoD in the RL fat and PAI-1 might be an indirect consequence of ApoD's effect on TNF-α and insulin levels, as they in turn modulate PAI-1 [55] .
In conclusion, our study is the first to suggest a role for the ApoD protein in AT. ApoD accumulation in the three AT examined in our study correlated with improved systemic metabolic factors, including insulin sensitivity and inflammation. However, only accumulation to the RL fat depot was simultaneously correlated to all of these factors in severely obese women.
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